Company Filing History:
Years Active: 2016-2017
Title: Innovations by Joseph Patterson in Vascular Treatments
Introduction
Joseph Patterson is an accomplished inventor based in New Haven, CT (US). He has made significant contributions to the field of medical treatments, particularly in the area of vascular health. With a total of 2 patents, Patterson's work focuses on innovative methods to address neointimal stenosis.
Latest Patents
Patterson's latest patents include compositions and methods for treating and preventing neointimal stenosis. These methods involve the use of a TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof. The goal is to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can be utilized to prevent or inhibit neointimal stenosis or restenosis, particularly after procedures such as angioplasty, vascular grafts, or stenting. Additionally, Patterson has developed methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also part of his innovative work.
Career Highlights
Joseph Patterson is affiliated with Yale University, where he continues to advance research in vascular treatments. His work has garnered attention for its potential to improve patient outcomes in vascular health.
Collaborations
Patterson has collaborated with notable colleagues, including Christopher K Breuer and Tarek M Fahmy, to further enhance the impact of his research.
Conclusion
Joseph Patterson's innovative contributions to the field of vascular treatments demonstrate his commitment to improving medical outcomes through research and invention. His patents reflect a significant advancement in the methods for treating neointimal stenosis, showcasing the importance of innovation in healthcare.